Running out of cash can end trial prematurely. So far the company hasn't been able to put up the $6.5 mil surety bond, is potentially losing Samsung with $35 mil in past due debt. They won't have their clinical data for the HIV BLA, won't have inventory for trials, and don't have cash to pay Einstein. That could end the trial or have Einstein hold up the data until they get paid. Cash may dictate this outcome.
News 
Market Data 
Discover 
AI
